Revvity
RVTY · NYSELaboratory Analytical Instruments · Fiscal year ends Dec 29
Revvity reported revenue of $2.9B in the fiscal year ended Dec 2025, up 3.7% from the year before. Operating income was $357M, an operating margin of 12.5%, and net income was $241M. Operating cash flow of $583M less capital expenditure of $74M left free cash flow of $509M. Net debt was $2.3B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.3B | $2.8B | $2.8B | $2.9B |
| Gross profit | $2.4B | $2B | – | – | – |
| Research & development | $200M | $222M | $217M | $197M | $216M |
| Selling, general & admin | $975M | $1B | $1B | $994M | $992M |
| Operating income | $1.3B | $743M | $301M | $347M | $357M |
| Interest expense | – | $104M | $99M | $96M | $92M |
| Pre-tax income | $1.2B | $652M | $183M | $316M | $268M |
| Income tax | $314M | $139M | $3M | $33M | $28M |
| Net income | $943M | $569M | $693M | $270M | $241M |
| Diluted EPS | 8.08 | 4.50 | 5.55 | 2.20 | 2.07 |
| Diluted shares | 117M | 126M | 125M | 123M | 117M |
Balance sheet
| Fiscal year | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $603M | $454M | $913M | $1.2B | $920M |
| Receivables | $708M | $613M | $633M | $632M | $745M |
| Inventory | $426M | $405M | $428M | $368M | $379M |
| Current assets | $2.4B | $3.3B | $3B | $2.3B | $2.2B |
| Net PP&E | $486M | $483M | $510M | $482M | $479M |
| Goodwill | $6.6B | $6.5B | $6.5B | $6.5B | $6.6B |
| Total assets | $15B | $14.1B | $13.6B | $12.4B | $12.2B |
| Payables | $325M | $273M | $204M | $167M | $185M |
| Deferred revenue | $185M | $30M | $23M | $140M | $159M |
| Current liabilities | $1.2B | $1.5B | $1.5B | $653M | $1.3B |
| Short-term debt | $4M | $471M | $722M | $242,000 | $589M |
| Long-term debt | $5B | $3.9B | $3.2B | $3.2B | $2.6B |
| Total liabilities | $7.9B | $6.7B | $5.7B | $4.7B | $4.9B |
| Shareholders' equity | $7.1B | $7.4B | $7.9B | $7.7B | $7.3B |
Cash flow
| Fiscal year | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $1.4B | $680M | $91M | $628M | $583M |
| Capital expenditure | $86M | $86M | $81M | $87M | $74M |
| Free cash flow | $1.3B | $594M | $10M | $542M | $509M |
| Depreciation & amortisation | $311M | $427M | $432M | $428M | $405M |
| Stock-based compensation | $30M | $52M | $41M | $38M | $23M |
| Share buybacks | $73M | $81M | $389M | $370M | $821M |
| Dividends paid | $32M | $35M | $35M | $34M | $33M |
| Dividend per share | – | 0.28 | 0.28 | 0.28 | 0.28 |
Key ratios
| Fiscal year | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | −13.5% | −16.9% | 0.2% | 3.7% |
| Operating income growth (YoY) | – | −41.0% | −59.5% | 15.4% | 2.9% |
| EPS growth (YoY) | – | −44.3% | 23.3% | −60.4% | −5.9% |
| Gross margin | 63.6% | 60.1% | – | – | – |
| Operating margin | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% |
| Net margin | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% |
| Return on equityBlank when equity is negative | 13.2% | 7.7% | 8.8% | 3.5% | 3.3% |
| ROCEEBIT ÷ (assets − current liabilities) | 9.1% | 5.9% | 2.5% | 3.0% | 3.3% |
| Free cash flow margin | 34.6% | 17.9% | 0.4% | 19.7% | 17.8% |
| Cash conversion (CFO ÷ net income) | 1.50x | 1.19x | 0.13x | 2.32x | 2.42x |
| Receivable days | 68 | 68 | 84 | 84 | 95 |
| Inventory days | 112 | 112 | – | – | – |
| Payable days | 85 | 75 | – | – | – |
| Interest cover | – | 7.14x | 3.04x | 3.60x | 3.87x |
| Debt ÷ equity | 0.70x | 0.60x | 0.50x | 0.41x | 0.44x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $4.4B | $3.9B | $3B | $2B | $2.3B |
| Current ratio | 2.01x | 2.13x | 2.07x | 3.60x | 1.68x |
Recent filings
More in Laboratory Analytical Instruments
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.